Prosztatarák: vizsgálatok itt: Kína
253 trials · From ClinicalTrials.gov, checked 2026. november 15.. Ask the study team whether a trial fits you.
- 1. fázisTaking peopleA Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer
- Where
- Beijing
- Életkor
- 18 év to 85 év
- People
- 12
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT07339267 - 1/2. fázisNot yet taking people in KínaStudy of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
- Where
- Changsha, Chengdu, Wuhan
- Életkor
- 18 év to 130 év
- People
- 283 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07181161 · EU 2024-520026-11-00 - 2. fázisTaking peopleStudy of PF-07248144 in Advanced or Metastatic Solid Tumors
- Where
- Beijing, Changchun, Guangzhou, Xi’an
- Életkor
- 18 év and over
- People
- 320 worldwide
- Run by
- Pfizer
See details and how to joinNCT04606446 - 1/2. fázisTaking peopleA Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Where
- Baoding, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Taizhou, Tianjin, Wuhan, Xi’an, Xinxiang, Zhengzhou
- Életkor
- 18 év and over
- People
- 862 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT05914116 - 3. fázisTaking peopleAn Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
- Where
- Beijing, Guangzhou, Shanghai
- Életkor
- 18 év to 100 év
- People
- 450 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT05939414 · EU 2022-502956-29-00 - No phaseNot yet taking people in KínaNon-inferiority Trial Omitting Drainage After Robot-assisted Radical prostatectomY
- Where
- Beijing, Hefei, Shanghai
- People
- 400
- Run by
- Shanghai East Hospital
See details and how to joinNCT07887321 - 3. fázisTaking peopleA Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- Where
- Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jiaxing, Kunming, Nanchong, Nanjing, Nantong, Ningbo, Shanghai, Tianjin, Ürümqi, Wenzhou, Wuhan, Wuxi, Xi'an, Yantai
- Életkor
- 18 év and over
- People
- 1314 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06136650 · EU 2023-504957-11-00 - 1/2. fázisTaking peopleStudy of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer
- Where
- Jinan, Shanghai
- Életkor
- 18 év and over
- People
- 307
- Run by
- Evopoint Biosciences Inc.
See details and how to joinNCT06702995 - 3. fázisNot yet taking people in KínaAZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
- Where
- Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanjing, Shanghai, Shenyang, Suzhou, Wuhan, Xi'an
- Életkor
- 18 év and over
- People
- 670 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07611110 - 1. fázisTaking peopleA Phase I Trial of A-CAR032 in Participants With mCRPC
- Where
- Beijing, Hangzhou, Wuhan, Xuzhou
- Életkor
- 18 év and over
- People
- 27
- Run by
- Shanghai AbelZeta Ltd.
See details and how to joinNCT07344311 - 3. fázisTaking peopleA Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
- Where
- Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Hefei, Nanchang, Nanjing, Shanghai, Wenzhou, Wuhan, Wuhu, Yantai
- Életkor
- 18 év and over
- People
- 736 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07365995 · EU 2025-524445-27-00 - 3. fázisTaking peopleStudy Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
- Where
- Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Shenyang, Tianjin, Wuhan
- Életkor
- 18 év to 100 év
- People
- 940 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06855277 - 3. fázisNot yet taking people in KínaSaruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
- Where
- Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Jiaxing, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Nantong, Ningbo, Qingdao, Shandong, Shanghai, Wenzhou, Wuhan, Xi'an
- Életkor
- 18 év and over
- People
- 1330 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07711002 · EU 2026-526275-38-00 - 3. fázisNot yet taking people in KínaA Phase 3 Study of Deutenzalutamide in Patients With High-Risk BCR Prostate Cancer
- Where
- Beijing, Chengdu, Shanghai
- Életkor
- 18 év and over
- People
- 1044
- Run by
- Hinova Pharmaceuticals Inc.
See details and how to joinNCT07875881 - 3. fázisTaking peopleA Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
- Where
- Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Jinan, Jinhua, Lanzhou, Nanchang, Ningbo, Shanghai, Shenyang, Sichuan, Suining, Tianjin, Wuhan, Wuhu, Xiamen, Yangzhou, Zhuhai
- Életkor
- 18 év and over
- People
- 700 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06952803 · EU 2024-513586-39-00 - 3. fázisFut, nem toborozThis Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
- Where
- Beijing, Changsha, Chongqing, Guangzhou, Hangzhou, Huai'an, Jinan, Lanzhou, Nanjing, Nantong, Ningbo, Shanghai, Suining, Suzhou, Wenzhou, Wuhan, Wuhu, Xi’an
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Pfizer
See details and how to joinNCT07028853 · EU 2024-519369-24-00 - 1. fázisTaking peopleDEC003M in Prostate Cancer
- Where
- Beijing, Chengdu, Chongqing, Hangzhou, Suzhou, Wenzhou
- Életkor
- 18 év and over
- People
- 110
- Run by
- Hangzhou DAC Biotechnology Co., Ltd.
See details and how to joinNCT07657806 - 2. fázisTaking peopleSafety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Where
- Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jiaxing, Jinan, Nanjing, Nantong, Ningbo, Wenzhou, Wuhan
- Életkor
- 18 év and over
- People
- 182
- Run by
- TransThera Sciences (Nanjing), Inc.
See details and how to joinNCT07871110 - 1/2. fázisTaking peoplePhase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
- Where
- Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Shanghai, Suzhou, Tianjin, Wuhan, Wuxi, Zhengzhou
- Életkor
- 18 év and over
- People
- 90
- Run by
- Bivision Pharmaceuticals, Inc.
See details and how to joinNCT06139575 - 1/2. fázisTaking peopleAn Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 188 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07206056 · EU 2025-521880-10-00 - No phaseTaking peopleDevelopment of an Intraoperative Adaptive Biopsy System for Prostate Cancer: Integrating Imaging Navigation With Metabolic Feedback for Dynamic Decision-Making
- Where
- Shanghai
- Életkor
- 55 év and over
- People
- 90
- Run by
- Shanghai Zhongshan Hospital
See details and how to joinNCT07856017 - No phaseNot yet taking people in KínaCascadeDiagnose Prostate MRI
- Where
- Guigang, Guilin, Liuzhou, Nanning, Wuzhou
- Életkor
- 18 év and over
- People
- 3000
- Run by
- First Affiliated Hospital of Guangxi Medical University
See details and how to joinNCT07844304 - 1. fázisTaking peoplePhase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
- Where
- Beijing, Fuzhou, Hangzhou, Shanghai, Zhengzhou
- Életkor
- 18 év and over
- People
- 88 worldwide
- Run by
- Acerand Therapeutics (Hong Kong) Limited
See details and how to joinNCT06801236 - 1. fázisTaking peopleA Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer
- Where
- Shanghai
- Életkor
- 18 év to 80 év
- People
- 320 worldwide
- Run by
- Jiangsu HengRui Medicine Co., Ltd.
See details and how to joinNCT07711184 - 2. fázisTaking peopleStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Where
- Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Shanghai, Shenyang, Wuhan, Xi'an, Zhengzhou
- Életkor
- 18 év to 130 év
- People
- 454 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00